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EDITORIAL
Fibromyalgia: A Never-Ending Story of Central and Peripheral Pain Mechanisms
P. Sarzi-Puttini and F. Atzeni
Fibromyalgia (FM) is a complex of peripheral
and central pain mechanisms that cause and maintain
the wide range of symptoms characterizing the clinical
history of patients with FM (1,2). The disease is easy to
diagnose, but it is surprisingly difficult to explain its
underlying pathophysiologic mechanisms. Many pain
clinicians still believe that unexplained benign chronic
pain is a disease in itself that does not require an
explanation, and therefore they concentrate simply on
trying to treat it successfully regardless of what it may be
called: chronic widespread pain, FM, or a type of
psychoaffective or somatoform disorder (2,3).
The pathophysiologic basis of FM remains a
matter of debate, partially because it is usually claimed
that although FM is severe and widespread in nature, it
is not associated with any identifiable lesion of peri-
pheral and/or central tissue. Furthermore, patients with
FM describe their pain mainly in “neuropathic” terms,
i.e., verbal descriptors of the type used by patients with
peripheral neuropathic lesions. Many investigators con-
tinue to report peripheral tissue abnormalities, including
anomalies in muscle tissue, the autonomic nervous sys-
tem, and immunity.
Several years ago, Caro et al (4) reported a
significant association between FM and electrodiagnos-
tic and clinical signs of a demyelinating peripheral
nervous system injury similar to that seen in patients
with chronic inflammatory demyelinating polyneurop-
athy (CIDP). In this issue of Arthritis & Rheumatology,
Caro and colleagues (5) show that the loss of epidermal
nerve fiber density (ENFD) is a diffuse proximal and
distal process in patients with FM, and that nerve fiber
length may also be important, with distal sites being at
greater risk. A reduction in ENFD is often (but not
always) associated with significant neuropathic pain
(hence the name small fiber neuropathy [SFN]), and it
can reasonably be expected to give rise to a clinically
detectable loss of skin sensation (so-called negative
sensory phenomena) rather than painful peripheral
symptoms (positive sensory phenomena) (5). However,
SFN is associated with both, and it is thought that the
painful peripheral symptoms of SFN are attributable to
the disproportionate hyperexcitability of lesioned (but
still functioning) primary small nerve fibers surrounded
by a structurally normal but physiologically hyperexcit-
able group of secondary small nerve fibers that respond
collaterally. The strength of the current study by Caro et
al is that they demonstrate that the peripheral nervous
system is an important contributor to the symptoms and
chronicity of FM, which also implies the significant
contribution of small fiber neuropathy. The limitation of
the study by Caro and colleagues is that, after excluding
certain metabolic and congenital lesions that are known
to reduce ENFD, we are left with a heterogeneous group
of disorders with a final common pathway that is prob-
ably immune mediated.
The demonstration of an association between FM
and SFN may therefore support the view held by several
investigators that FM has an immunopathogenic com-
ponent that functionally affects the skin and sympathetic
nervous system. It is at least theoretically possible that
FM is characterized by a cytokine-related lesion, as
indicated by the inverse correlation between serum
interleukin-2 receptor (IL-2R) levels and calf ENFD. It
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is well known that cytokines play a role in rheumatic
diseases, and it has often been suggested that they
mediate injury in FM. Bazzichi et al (6) observed high
IL-10, IL-8, and tumor necrosis factor  levels in pa-
tients with FM, and intravenous infusion of IL-2 can give
rise to a clinical picture that is similar to FM in some
patients with cancer (7). Furthermore, it is interesting to
note that proinflammatory cytokines may also be among
the most likely causes of SFN, especially “idiopathic”
SFN.
However, there are other ideas concerning the
pathophysiologic mechanisms inducing pain and the
constellation of symptoms characterizing FM. FM ap-
pears to involve disordered central afferent processing,
and although its major symptoms are multifocal pain,
fatigue, sleep disturbances, and cognitive or memory
disorders, other symptoms may include psychologic dis-
tress, impaired functioning, and sexual dysfunction. The
pathophysiology of FM is still unknown, but it is believed
to be largely central in nature, i.e., central mechanisms
enhance the perception of pain or modulate it differen-
tially between individuals (1,2). The common biologic
hallmark of such “centrally driven” conditions is that the
central nervous system of most patients is affected by
widespread hyperalgesia that can be quantified by means
of sensory testing and corroborated by functional neu-
roimaging studies (8).
Certain genes seem to be involved in turning up
the “gain” of pain processing and identify one cause of a
“chronic pain–prone phenotype.” Another hallmark of
chronic pain is hypersensitivity to nonpainful stimuli in
sensitized patients, and recent evidence suggests that
genetic factors may contribute to individual differences
in pain sensitivity, the risk of developing painful clinical
conditions, and the efficacy of pain treatments. Consis-
tent with previous findings, Martinez-Jauand et al (9)
showed that haplotypes of the catechol-O-methyl-
transferase (COMT) and genotypes of the Val158Met
polymorphism play a key role in pain sensitivity in
patients with FM. Finally, it has been claimed that FM
symptoms may be related to stress or may simply be an
expression of a pain-related syndrome associated with
anxiety or depression (10).
In conclusion, the condition that we call FM may
be at the crossroads of different pathophysiologic situa-
tions with a common clinical background phenotype,
and the development of FM and other centralized pain
states may be triggered by a familial or genetic predis-
position or environmental factors.
Where does FM originate? Is it attributable to a
genetic and/or familial predisposition, a stress-related
personality disorder, a psychoaffective disorder, or a
posttraumatic stress disorder? FM may be associated
with all or none of these factors, or just one may reflect
and affect the nociceptive system. All we can do is
continue to look for tissue abnormalities and central
processing alterations in an attempt to discover which
come first and then develop the best therapeutic (or,
even better, preventive) strategy for the 2–3% of the
population with this disease.
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